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E-mail: elenicelli@yahoo.grWe are grateful to Gonzalez-Quijada et al. [1] for providing
novel insight into the long-lasting infection hypothesis in their
study. Bearing in mind that several controversies have arisen
over the years in this ﬁeld, we believe that some issues need to
be further clariﬁed before safe conclusions can be reached.
Firstly, a large amount of seroepidemiologic, histopathologic,
molecular and animal studies have implicated Chlamydia pneu-
moniae and cytomegalovirus in atherosclerosis by direct and
indirect mechanisms [2,3]. Thus, the negative result of the
present study needs to be addressed and clariﬁed by the au-
thors. This result may be attributed to the method of detection,
as IgG antibodies to C. pneumoniae and cytomegalovirus are
present in most elderly patients (approximately 80% and 95%,
respectively, in their study).
Secondly, the authors need to further clarify the deﬁnition
and process of patient classiﬁcation in atherosclerotic cardio-
vascular or cerebrovascular disease. Was this classiﬁcation part
of the study’s procedures, or were patient’s records retro-
spectively evaluated? Were “cardiovascular specialists” the pa-
tient’s physicians? Which criteria were used for the deﬁnition ofClinical Microbiology and Infection © 2014 European Society of Catherosclerotic cardiovascular disease? How many patients
were classiﬁed on the basis of imaging techniques?
Thirdly, the study’s population represents a heterogeneous
group with signiﬁcant differences between control parameters
in patients with and without cardiovascular disease. To that
end, a multivariate model including all factors that differed
signiﬁcantly between the two groups and using the presence of
the cardiovascular disease as a dependent variable would be
necessary in order to better understand the ﬁndings of the
present study. A subgroup analysis discriminating between pa-
tients with cardiovascular and cerebrovascular disease would
be also interesting, as their table 3 shows no signiﬁcant differ-
ence between Coxiella burnetii–seropositive and –seronegative
patients in cardiovascular disease incidence. In addition, the
authors mention that C-reactive protein was also measured.
However, the results are not presented and not included in the
analysis.
Lastly, and most importantly, the cross-sectional nature of
the present study limits its clinical usefulness. The hypothesis
that microorganisms are “innocent bystanders” and not aetio-
logical causes of atherosclerosis [3] is even more likely in the
present study. When both factors are detected in a large
number of patients, the probability of their “innocent” coex-
istence is even larger.
In conclusion, these issues need to be carefully addressed by
the authors in order to provide robust evidence for the design
of larger prospective studies focusing on a therapeutic or
preventive approach.
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